ClinicalTrials.gg
TerminatedNCT01722292Updated Dec 28, 2018Results posted

A Study of LY2940680 in Small Cell Lung Cancer

A Phase 1/2 interventional study of LY2940680 and Carboplatin in Small Cell Lung Carcinoma, sponsored by Eli Lilly and Company. Terminated at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-28.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Change in clinical strategy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company — none open to participants now, 1 under way, none of them phase 3. Small Cell Lung Carcinoma · Eli Lilly and Company.

Enrollment
8th of 12
26 · median 56
Started
2013
the only one that year
Phase 1/2
3 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 1/2, and was the 8th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

None of the 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company is open now. The open studies under Small Cell Lung Carcinoma, anywhere →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company as a file.
02

Study summary

The purpose of this study is to find a recommended dose of LY2940680 that can be safely given in combination with etoposide and carboplatin followed by LY2940680 alone in participants with extensive-disease small cell lung cancer. The study will also compare progression-free survival in participants who are administered etoposide, carboplatin and LY2940680 followed by LY2940680 alone versus etoposide, carboplatin, and placebo followed by placebo alone.

03

Conditions studied

  • Small Cell Lung Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of Small Cell Lung Cancer (SCLC), including malignant pleural effusion that is extensive stage per the International Staging System
  • Performance status of 0 to 1 on the (ECOG) performance status schedule
  • No prior systemic chemotherapy, immunotherapy, or biological therapy for SCLC
  • Prior radiation therapy allowed to \<25% of the bone marrow. Participants who have received prior radiation to the whole pelvis or chest for the treatment of SCLC are not eligible
  • At least 1 unidimensionally meeting (RECIST) version 1.1
  • Adequate organ function including the following:

    • Adequate bone marrow reserve: (ANC) ≥1.5 x 10\^9/ liter (L), ≥100 x 10\^9/L, and ≥9 grams/deciliter (g/dL)
    • Hepatic: ≤1.5 times the (ULN), alkaline phosphatase (AP), Serum (ALT) and aspartate transaminase (AST) ≤3.0 x ULN (AP, AST, and ALT ≤5 x ULN is acceptable if liver has tumor involvement)
    • Renal: calculated (CrCl) ≥50 milliliters per minute (mL/min) based on the standard Cockcroft and Gault formula
  • Estimated of at least 12 weeks
  • For women: Must be surgically sterile, , or compliant with a medically approved regimen during and for 6 months after the treatment period; must have a negative serum pregnancy test within 7 days before study enrollment. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period
  • Availability of a tumor tissue sample
  • Able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have previously participated in a study involving LY2940680
  • Have previously received treatment with carboplatin or etoposide
  • Have a mixed histological diagnosis of SCLC and Non-Small Cell Lung Cancer (NSCLC)
  • Have a serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the participant's ability to adhere to the protocol
  • Have an active infection [≥38.5 degrees Celsius and/or receiving Intravenous (IV) antibiotic therapy]
  • Have a serious cardiac condition
  • Have had a prior other than SCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. Participants with a history of non- prostate cancer, including biochemical relapse only, will be eligible even if diagnosed less than 5 years previously
  • Symptomatic central nervous system (CNS) metastases and asymptomatic requiring concurrent therapy. Treated stable CNS metastases are allowed; the participant must be stable after radiotherapy for ≥2 weeks and off of corticosteroids for ≥1 week
  • Presence of third-space fluid collections that cannot be controlled prior to study entry
  • Significant weight loss (that is, ≥10%) over the 6-week period prior to study entry
  • Concurrent administration of any other antitumor therapy. An exception will be made for non-metastatic prostate cancer participants continuing androgen blockade therapy only or breast cancer participants continuing antiestrogen therapy only (for example, an aromatase inhibitor)
  • Females who are breastfeeding
  • Have interval (QTc) of >470 millisecond (msec) on screening (ECG)
  • Have received medications that are strong inhibitors of Cytochrome P450 3A4 () within 7 days prior to receiving study drug
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Phase 1b: LY2940680 + C + E

    Phase 1b Dose Escalation: Cycles 1-6 (21 day cycles) LY2940680 administered orally, once daily at escalating doses (100 milligrams \[mg\] up to 400 mg) in combination with etoposide (E) 100 milligram per square meter (mg/m\^2) administered by intravenous (IV) infusion on days 1, 2, 3 of each cycle and carboplatin (C) Area Under the Curve \[AUC\] 5 (mg•min/mL) administered by IV infusion on day 1 each cycle. Phase 1b Maintenance: Cycles 7+ (21 day cycles) LY2940680 administered orally, once daily at the same dose as induction. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.

    Drug: LY2940680 · Drug: Carboplatin · Drug: Etoposide

  • Placebo comparator
    Phase 2: Placebo + C + E

    Induction: Cycles 1-6 (21 day cycles) Placebo administered orally once daily in combination with etoposide 100 mg/m2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle. Maintenance: Cycles 7+ (21 day cycles) Placebo administered orally once daily. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.

    Drug: Carboplatin · Drug: Etoposide · Drug: Placebo

  • Experimental
    Phase 2: LY2940680 + C+ E

    Induction: Cycles 1-6 (21 day cycles) LY2940680 (dose to be determined in Phase 1b portion) administered orally once daily in combination with etoposide 100 mg/m\^2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle. Maintenance: Cycles 7+ (21 day cycles). LY2940680 (dose to be determined in Phase 1 portion) administered orally once daily.

    Drug: LY2940680 · Drug: Carboplatin · Drug: Etoposide

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1b: Recommended Phase 2 Dose of LY2940680: Maximum Tolerated Dose (MTD)

    MTD was defined as the highest tested dose that has \<33% probability of causing a dose-limiting toxicity(DLT). DLT was defined as an AE during Cycle 1 that is possibly related to the study drug and fulfills any one of the following criterion using the National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events(CTCAE),version 4.0:Grade 3 non-hematological toxicity except nausea, vomiting, constipation, diarrhea, fatigue, or anorexia that is manageable with appropriate care,transient(i.e., ≤5 days) Grade 3 elevations of alanine aminotransferase(ALT) and/or aspartate aminotransferase(AST), without evidence of other hepatic injury, in the setting of preexisting hepatic metastasis, ≥Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia of any duration,CTCAE Grade 4 hematological toxicity of \>5 days duration and any febrile neutropenia. any other significant toxicity deemed by the primary investigator and Lilly clinical research personnel to be dose-limiting.

    Time frame: Baseline to Completion of the Phase 1b (Up To 12 Months)

  2. Phase 2: Progression-Free Survival

    Time frame: Randomization to Measured Progressive Disease or Death of Any Cause (Estimated as 18 Months)

Secondary outcomes

  1. Phase 1b and 2: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2940680, LSN3185556 at the Recommended Dose

    Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours

  2. Phase 1b and 2: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Carboplatin and Etoposide at the Recommended Dose

    Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours

  3. Phase 1b and 2: Pharmacokinetics: Area Under the Curve ( AUC₀-₂₄) for LY2940680 and LSN3185556 at the Recommended Dose

    Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours

  4. Phase 1b and 2: Pharmacokinetics: Area Under the Curve ( AUC₀-₂₄) for Etoposide and as AUC₀-₆ for Carboplatin at the Recommended Dose

    Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours

  5. Phase 1b: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])

    ORR was defined as the percentage of all randomized participants with the best overall response of PR or CR using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Tumor marker results must have normalized. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.

    Time frame: Baseline to Study Completion Up to 39 Months

  6. Phase 1b: Percentage Inhibition of Expression Levels of Gli1 in Skin Cells

    The gene expression data (Gli1) was normalized and the level of percentage of Gli1 inhibition post treatment was calculated.

    Time frame: Baseline, Cycle 2 Day 1, Cycle 7 Day 1

  7. Phase 2: Overall Survival

    Time frame: Randomization to Study Completion (Estimated as 38 Months)

  8. Phase 2: Percent Change in Tumor Size (CTS)

    Time frame: Randomization to End of Cycle 2 (Estimated as 24 Months)

  9. Phase 2: Number of Participants With a Complete or Partial Tumor Response (Overall Response Rate)

    Time frame: Randomization to Study Completion (Estimated as 38 Months)

  10. Phase 1b and 2: Pharmacokinetics: Time to Maximal Concentration (Tmax) of LY2940680 andLSN3185556 at the Recommended Dose

    Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours

  11. Phase 1b and 2: Pharmacokinetics: Time to Maximal Concentration (Tmax) of Carboplatin and Etoposide at the Recommended Dose

    Time frame: Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours

07

Results

Posted Dec 28, 2018
Limitations and caveats
Due to strategic reasons, the Phase 2 portion was not initiated, and further clinical development was stopped.

Participant flow

Participant flow — Overall Study
MilestonePhase 1b: 100 mg LY2940680 + C + EPhase 1b: 200 mg LY2940680 + C + EPhase 1B: 400 mg LY2940680 + C + E
Started6614
Received at least one dose of study drug6614
Completed6614
Not completed000

Outcome measures

PrimaryPhase 1b: Recommended Phase 2 Dose of LY2940680: Maximum Tolerated Dose (MTD)

MTD was defined as the highest tested dose that has \<33% probability of causing a dose-limiting toxicity(DLT). DLT was defined as an AE during Cycle 1 that is possibly related to the study drug and fulfills any one of the following criterion using the National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events(CTCAE),version 4.0:Grade 3 non-hematological toxicity except nausea, vomiting, constipation, diarrhea, fatigue, or anorexia that is manageable with appropriate care,transient(i.e., ≤5 days) Grade 3 elevations of alanine aminotransferase(ALT) and/or aspartate aminotransferase(AST), without evidence of other hepatic injury, in the setting of preexisting hepatic metastasis, ≥Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia of any duration,CTCAE Grade 4 hematological toxicity of \>5 days duration and any febrile neutropenia. any other significant toxicity deemed by the primary investigator and Lilly clinical research personnel to be dose-limiting.

Time frame:
Baseline to Completion of the Phase 1b (Up To 12 Months)
Reported as:
Number · milligrams (mg)
Phase 1b: Recommended Phase 2 Dose of LY2940680: Maximum Tolerated Dose (MTD)
milligrams (mg)Phase 1b
Phase 1b: Recommended Phase 2 Dose of LY2940680: Maximum Tolerated Dose (MTD)400
PrimaryPhase 2: Progression-Free Survival
Time frame:
Randomization to Measured Progressive Disease or Death of Any Cause (Estimated as 18 Months)

No measurements were reported for this outcome.

SecondaryPhase 1b and 2: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2940680, LSN3185556 at the Recommended Dose
Time frame:
Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Phase 1b and 2: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2940680, LSN3185556 at the Recommended Dose
microgram per milliliter (µg/mL)Phase 1b: 100 mg LY2940680 + C + EPhase 1b: 200 mg LY2940680 + C + EPhase 1B: 400 mg LY2940680 + C + E
LY2940680 Cycle 1, Day 10.491 ± 641.01 ± 361.56 ± 35
LY2940680 Cycle 2, Day 10.578 ± 711.16 ± 663.29 ± 33
LSN3185556 Cycle 1, Day 10.444 ± 330.737 ± 1381.75 ± 47
LSN3185556 Cycle 2, Day 11.6 ± 352.1 ± 906 ± 59
SecondaryPhase 1b and 2: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Carboplatin and Etoposide at the Recommended Dose
Time frame:
Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Phase 1b and 2: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Carboplatin and Etoposide at the Recommended Dose
microgram per milliliter (µg/mL)Phase 1b: LY2940680 + C + E
Total Carboplatin Cycle 1, Day 116.7 ± 33
Total Carboplatin Cycle 2, Day 113.1 ± 42
Etoposide Cycle 1, Day 120.9 ± 18
Etoposide Cycle 2, Day 118.4 ± 28
SecondaryPhase 1b and 2: Pharmacokinetics: Area Under the Curve ( AUC₀-₂₄) for LY2940680 and LSN3185556 at the Recommended Dose
Time frame:
Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Reported as:
Geometric mean · Hour*microgram per milliliter (h.µg/mL)
Phase 1b and 2: Pharmacokinetics: Area Under the Curve ( AUC₀-₂₄) for LY2940680 and LSN3185556 at the Recommended Dose
Hour*microgram per milliliter (h.µg/mL)Phase 1b: 100 mg LY2940680 + C+ EPhase 1b: 200 mg LY2940680 + C+ EPhase 1b: 400 mg LY2940680 + C+ E
LY2940680 Cycle 1, Day 16.34 ± 578.96 ± 3915.9 ± 27
LY2940680 Cycle 2, Day 17.86 ± 6715.5 ± 6437.6 ± 43
LSN3185556 Cycle 1, Day 17.23 ± 4916.2 ± 6726 ± 37
LSN3185556 Cycle 2, Day 122.7 ± 5831.1 ± 11192.5 ± 72
SecondaryPhase 1b and 2: Pharmacokinetics: Area Under the Curve ( AUC₀-₂₄) for Etoposide and as AUC₀-₆ for Carboplatin at the Recommended Dose
Time frame:
Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Reported as:
Geometric mean · Hour*microgram per milliliter (h.µg/mL)
Phase 1b and 2: Pharmacokinetics: Area Under the Curve ( AUC₀-₂₄) for Etoposide and as AUC₀-₆ for Carboplatin at the Recommended Dose
Hour*microgram per milliliter (h.µg/mL)Phase 1b: LY2940680 + C+ E
Total Carboplatin Cycle 1, Day 137.2 ± 23
Total Carboplatin Cycle 2, Day 132.0 ± 25
Etoposide Cycle 1, Day 1104 ± 22
Etoposide Cycle 2, Day 196.1 ± 20
SecondaryPhase 1b: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])

ORR was defined as the percentage of all randomized participants with the best overall response of PR or CR using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Tumor marker results must have normalized. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.

Time frame:
Baseline to Study Completion Up to 39 Months
Reported as:
Mean · percentage of participants
Phase 1b: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
percentage of participantsPhase 1b: 100 mg LY2940680 + C+ EPhase 1b: 200 mg LY2940680 + C+ EPhase 1b: 400 mg LY2940680 + C+ E
Phase 1b: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])50 (16.4 to 83.6)50 (16.4 to 83.6)57.1 (35.4 to 78.9)
SecondaryPhase 1b: Percentage Inhibition of Expression Levels of Gli1 in Skin Cells

The gene expression data (Gli1) was normalized and the level of percentage of Gli1 inhibition post treatment was calculated.

Time frame:
Baseline, Cycle 2 Day 1, Cycle 7 Day 1
Reported as:
Median · Percentage of Gli 1 Inhibition
Phase 1b: Percentage Inhibition of Expression Levels of Gli1 in Skin Cells
Percentage of Gli 1 InhibitionPhase 1b: 100 mg LY2940680Phase 1b: 200 mg LY2940680Phase 1b: 400 mg LY2940680
Phase 1b: Percentage Inhibition of Expression Levels of Gli1 in Skin Cells94.7 (75.9 to 94.9)95.1 (94.5 to 97.2)94.8 (90.7 to 97.3)
SecondaryPhase 2: Overall Survival
Time frame:
Randomization to Study Completion (Estimated as 38 Months)

No measurements were reported for this outcome.

SecondaryPhase 2: Percent Change in Tumor Size (CTS)
Time frame:
Randomization to End of Cycle 2 (Estimated as 24 Months)

No measurements were reported for this outcome.

SecondaryPhase 2: Number of Participants With a Complete or Partial Tumor Response (Overall Response Rate)
Time frame:
Randomization to Study Completion (Estimated as 38 Months)

No measurements were reported for this outcome.

SecondaryPhase 1b and 2: Pharmacokinetics: Time to Maximal Concentration (Tmax) of LY2940680 andLSN3185556 at the Recommended Dose
Time frame:
Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Reported as:
Median · Hour (h)
Phase 1b and 2: Pharmacokinetics: Time to Maximal Concentration (Tmax) of LY2940680 andLSN3185556 at the Recommended Dose
Hour (h)Phase 1b: 100 mg LY2940680 + C+ EPhase 1b: 200 mg LY2940680 + C+ EPhase 1b: 400 mg LY2940680 + C+ E
LY2940680 Cycle 1, Day 12.05 (1 to 3.98)2.01 (1.03 to 2.05)1.51 (0.5 to 6)
LY2940680 Cycle 2, Day 12.96 (0.08 to 5.83)4 (1.88 to 4.08)1 (0.5 to 6)
LSN3185556 Cycle 1, Day 26.14 (2 to 24.03)5.87 (2.07 to 24.97)6 (2.05 to 24)
LSN3185556 Cycle 2, Day 22.3 (0 to 4)4.08 (4 to 23.83)2.21 (0.5 to 6)
SecondaryPhase 1b and 2: Pharmacokinetics: Time to Maximal Concentration (Tmax) of Carboplatin and Etoposide at the Recommended Dose
Time frame:
Cycle (C)1 Day (D) 1:Predose,0.5 ,1, 2, 4, 6, 8h; C2 D1:Pr,0.5,1,2,4,6,8 hours
Reported as:
Median · Hour (h)
Phase 1b and 2: Pharmacokinetics: Time to Maximal Concentration (Tmax) of Carboplatin and Etoposide at the Recommended Dose
Hour (h)Phase 1b: LY2940680 + C+ E
Total Carboplatin Cycle 1, Day 10.5 (0.42 to 1.08)
Total Carboplatin Cycle 2, Day 10.5 (0.42 to 1.05)
Etoposide Cycle 1, Day 10.96 (0.48 to 1.5)
Etoposide Cycle 2 ,Day 10.99 (0.33 to 1.17)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: 100 mg LY2940680 + C + E—3/6 (50%)6/6 (100%)
Phase 1b: 200 mg LY2940680 + C + E—6/6 (100%)6/6 (100%)
Phase 1b: 400 mg LY2940680 + C + E—8/14 (57.1%)14/14 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPhase 1b: 100 mg LY2940680 + C + EPhase 1b: 200 mg LY2940680 + C + EPhase 1b: 400 mg LY2940680 + C + E
Febrile neutropeniaBlood and lymphatic system disorders2/61/60/14
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/62/60/14
PneumoniaInfections and infestations1/60/63/14
AnaemiaBlood and lymphatic system disorders0/61/60/14
NeutropeniaBlood and lymphatic system disorders1/60/61/14
ThrombocytopeniaBlood and lymphatic system disorders1/60/60/14
Ventricular extrasystolesCardiac disorders0/61/60/14
EnterocolitisGastrointestinal disorders1/60/60/14
NauseaGastrointestinal disorders0/61/60/14
PancreatitisGastrointestinal disorders0/61/60/14
Most frequent other events
Showing 10 of 123
Most frequent other events
EventPhase 1b: 100 mg LY2940680 + C + EPhase 1b: 200 mg LY2940680 + C + EPhase 1b: 400 mg LY2940680 + C + E
NeutropeniaBlood and lymphatic system disorders5/65/67/14
FatigueGeneral disorders4/63/611/14
NauseaGastrointestinal disorders2/64/610/14
ConstipationGastrointestinal disorders4/61/68/14
VomitingGastrointestinal disorders2/64/65/14
Oedema peripheralGeneral disorders1/64/62/14
Muscle spasmsMusculoskeletal and connective tissue disorders4/62/66/14
DysgeusiaNervous system disorders4/64/68/14
AnaemiaBlood and lymphatic system disorders2/63/68/14
ThrombocytopeniaBlood and lymphatic system disorders3/63/68/14

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Phase 1b: 100 mg LY2940680 + C +EPhase 1b: 200 mg LY2940680 + C + EPhase 1b: 400 mg LY2940680 + C + ETotal
Mean64.3 ± 9.3564.8 ± 11.9660.2 ± 12.1962.2 ± 11.33
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b: 100 mg LY2940680 + C +EPhase 1b: 200 mg LY2940680 + C + EPhase 1b: 400 mg LY2940680 + C + ETotal
Female33713
Male33713
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b: 100 mg LY2940680 + C +EPhase 1b: 200 mg LY2940680 + C + EPhase 1b: 400 mg LY2940680 + C + ETotal
Hispanic or Latino0101
Not Hispanic or Latino651425
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b: 100 mg LY2940680 + C +EPhase 1b: 200 mg LY2940680 + C + EPhase 1b: 400 mg LY2940680 + C + ETotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0213
White631322
More than one race0000
Unknown or Not Reported0101
Region of Enrollment
Region of Enrollment(participants)Phase 1b: 100 mg LY2940680 + C +EPhase 1b: 200 mg LY2940680 + C + EPhase 1b: 400 mg LY2940680 + C + ETotal
United States551020
United Kingdom1146
08

Study locations

14 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Northeast Georgia Cancer Care, LLC
    Athens, Georgia 30607, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • New York Oncology Hematology Associate
    Albany, New York 12206, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Clinical Research Unit (ITOR) Greenville Hospital System
    Greenville, South Carolina 29605, United States
  • Accelerated Comm. Oncology Research Network (ACORN)
    Memphis, Tennessee 38119, United States
  • The West Clinic
    Memphis, Tennessee 38120, United States
  • US Oncology
    The Woodlands, Texas 77380, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Northwest Cancer Specialists PC
    Vancouver, Washington 98684, United States
  • Yakima Valley Memorial Hospital
    Yakima, Washington 98902, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, SE1 9RT, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manchester, M20 4BX, United Kingdom
09

References and documents

Individual participant data

Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2018, 3 years 10 months after primary completion. A results delay was requested in May 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2012
First posted
Nov 6, 2012
Start
Jan 2013
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results delay requested
May 8, 2015
Results first posted
Dec 28, 2018
Last update
Dec 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01722292
Responsible party
Sponsor
First posted
Nov 6, 2012
Start date
Jan 2013
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Dec 28, 2018
Last update
Dec 28, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY2940680

Start the discussion